S P Henry

Summary

Affiliation: Isis Pharmaceuticals
Country: USA

Publications

  1. ncbi Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
    Scott P Henry
    Toxicology and Pharmacokinetics Department, Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Int Immunopharmacol 2:1657-66. 2002
  2. ncbi Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Birth Defects Res B Dev Reprod Toxicol 71:359-67. 2004
  3. ncbi Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits
    Scott P Henry
    Isis Pharmaceuticals Inc, Carlsbad, CA 92008, USA
    Birth Defects Res B Dev Reprod Toxicol 71:368-73. 2004
  4. ncbi Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88
    Joseph J Senn
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 314:972-9. 2005
  5. ncbi Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad, CA 92010, United States
    Toxicology 301:13-20. 2012
  6. ncbi Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides
    Scott P Henry
    Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Trends Pharmacol Sci 25:523-7. 2004
  7. ncbi Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Mutagenesis 17:201-9. 2002
  8. ncbi Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    S P Henry
    Isis Pharmaceuticals Inc, Department of Toxicology and Pharmacokinetics, Carlsbad, CA 92007, USA
    Curr Opin Investig Drugs 2:1444-9. 2001
  9. ncbi Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication
    S P Henry
    Isis Pharmaceuticals, Inc, Carlsbad, California 92008, USA
    Invest Ophthalmol Vis Sci 42:2646-51. 2001
  10. ncbi Chemically modified oligonucleotides exhibit decreased immune stimulation in mice
    S Henry
    Isis Pharmaceuticals, Inc, Carlsbad, California, USA
    J Pharmacol Exp Ther 292:468-79. 2000

Detail Information

Publications14

  1. ncbi Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
    Scott P Henry
    Toxicology and Pharmacokinetics Department, Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Int Immunopharmacol 2:1657-66. 2002
    ..Demonstration of this relationship underscores the importance of avoiding complement activation in patients to ensure the continued safe use of phosphorothioate oligodeoxynucleotides...
  2. ncbi Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    Birth Defects Res B Dev Reprod Toxicol 71:359-67. 2004
    ..Neither the human nor murine-specific antisense inhibitor of ICAM-1 produced any reproductive toxicity in mice, and exposure of fetus or pups was negligible...
  3. ncbi Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits
    Scott P Henry
    Isis Pharmaceuticals Inc, Carlsbad, CA 92008, USA
    Birth Defects Res B Dev Reprod Toxicol 71:368-73. 2004
    ..Thus, there was no dose-dependent exposure and maternal toxicity to ISIS 2302, but no reproductive toxicity in rabbits, and exposure of fetus or pups is negligible...
  4. ncbi Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88
    Joseph J Senn
    Isis Pharmaceuticals, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 314:972-9. 2005
    ..These data implicate a TLR-independent mechanism of activation for non-CpG 2'-MOE oligonucleotides...
  5. ncbi Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad, CA 92010, United States
    Toxicology 301:13-20. 2012
    ..Collectively, these data indicate that ISIS 113715-uptake by the proximal tubular epithelium has little or no effect on renal function at concentrations of 2600 μg/g...
  6. ncbi Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides
    Scott P Henry
    Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Trends Pharmacol Sci 25:523-7. 2004
    ....
  7. ncbi Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide
    Scott P Henry
    Isis Pharmaceuticals, Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Mutagenesis 17:201-9. 2002
    ..Furthermore, the absence of genotoxicity could not be ascribed to test system insensitivity or to an absence of exposure of the test system to ISIS 2302...
  8. ncbi Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    S P Henry
    Isis Pharmaceuticals Inc, Department of Toxicology and Pharmacokinetics, Carlsbad, CA 92007, USA
    Curr Opin Investig Drugs 2:1444-9. 2001
    ..This review will focus on the non-clinical pharmacokinetic and safety properties of 2'-O-methoxyethyl-modified oligonucleotides. Implications on the convenience and safe use of these compounds as therapeutic agents will be discussed...
  9. ncbi Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication
    S P Henry
    Isis Pharmaceuticals, Inc, Carlsbad, California 92008, USA
    Invest Ophthalmol Vis Sci 42:2646-51. 2001
    ..To compare the antiviral activity and ocular distribution of first- and second-generation antisense oligonucleotides intended for the treatment of cytomegalovirus (CMV) retinitis...
  10. ncbi Chemically modified oligonucleotides exhibit decreased immune stimulation in mice
    S Henry
    Isis Pharmaceuticals, Inc, Carlsbad, California, USA
    J Pharmacol Exp Ther 292:468-79. 2000
    ..Thus, chemical modifications appeared to increase the tolerability profile for these compounds that are representative of the second generation of antisense oligonucleotides...
  11. ncbi Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
    S P Henry
    Isis Pharmaceuticals, Inc, Carlsbad, California 92008, USA
    Toxicol Pathol 27:95-100. 1999
    ..In addition, there has been no evidence of genetic toxicity associated with ISIS 2302, and no changes in reproductive performance, fertility, or fetal development have been noted in animals treated with ISIS 2302 or ISIS 3082...
  12. ncbi Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
    S P Henry
    Department of Toxicology, Isis Pharmaceuticals Inc, Carlsbad, CA 92008, USA
    Toxicology 120:145-55. 1997
    ..In general, 10 and 50 mg/kg ISIS 2302 produced dose-dependent changes in clotting times and the kidney that were reversible, while 2 mg/kg ISIS 2302 produced no remarkable alterations...
  13. ncbi Fomivirsen: clinical pharmacology and potential drug interactions
    Richard S Geary
    Isis Pharmaceuticals, 1896 Faraday Avenue, Carlsbad, CA 92008, USA
    Clin Pharmacokinet 41:255-60. 2002
    ..The only reported warning is a recommendation against administration within 2 to 4 weeks of cidofovir treatment due to an increased risk of ocular inflammation...
  14. ncbi Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species
    Richard S Geary
    Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    Drug Metab Dispos 31:1419-28. 2003
    ..This favorable pharmacokinetic profile for ISIS 104838 provides guidance for clinical development and appears to support infrequent and convenient dose administration...